Ocrelizumab for the Treatment of Multiple Sclerosis: Safety, Efficacy, and Pharmacology.

ABSTRACT: The success of selective B-cells depleting therapies, as the anti-CD20 antibodies, in patients with multiple sclerosis (MS) has confirmed that B-cells are critical in the immune pathogenesis of the disease. Ocrelizumab, a humanized monoclonal antibody that selectively targets CD20+ B-cells, profoundly suppresses acute inflammatory disease activity, representing a highly effective therapy for relapsing-remitting multiple sclerosis (RRMS). It is also the first proven therapy able to slow disability progression in primary progressive multiple sclerosis (PPMS), particularly in patients with signs of acute radiological activity before being enrolled. Effectiveness has widely been demonstrated in randomized clinical trials (RCTs), and recently confirmed in open-label extension trials. Here, we r

SUBMITTER: Mancinelli CR 

PROVIDER: S-EPMC8331077 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature